Skip to main content
EJNMMI Research
Figure 5 | EJNMMI Research

Figure 5

From: [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

Figure 5

Representative immunohistochemical images of Ki-67 positive cells in HCT116 ( K - ras ) xenografts in mice treated with a lowest dose RO5126766 (0.1 mg/kg). (a) tumor morphology, visualized with H&E staining (left image) and corresponding Ki-67 positive staining (brown cells, right image) before the treatment start (baseline) and (b) after 3 days of treatment with RO5126766 (0.1 mg/kg). (c) Quantitative assessment of proliferating index of tumor cells in relation to RO5126766 treatment based on IHC staining of Ki-67 antigen of excised, acetone fixed frozen tumor tissue (*p < 0.05, n = 3).

Back to article page